Trudeau, M., Chapman, J., Guo, B., Clemons, M., Dent, R., Jong, R., . . . SCHOOL, D. M. (2020). A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.
استشهاد بنمط شيكاغوTrudeau, M.E, et al. A Phase I/II Trial of Epirubicin and Docetaxel in Locally Advanced Breast Cancer (LABC) On 2-weekly or 3-weekly Schedules: NCIC CTG MA.22. 2020.
MLA استشهادTrudeau, M.E, et al. A Phase I/II Trial of Epirubicin and Docetaxel in Locally Advanced Breast Cancer (LABC) On 2-weekly or 3-weekly Schedules: NCIC CTG MA.22. 2020.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.